Oncology billing services
A single infusion day can carry a drug claim worth thousands of dollars. We code administration, drug units and waste carefully to support payment on those claims.
Why oncology billing takes specialty knowledge
Oncology billing has more money riding on each claim than almost any other specialty. Drug costs are high, administration codes follow a strict hierarchy, and payers require prior authorization for most chemotherapy and immunotherapy regimens. A unit conversion error on a J-code or a missing JZ modifier can turn a large claim into a denial or an underpayment that nobody notices.
SFA Solutions reviews infusion documentation for start and stop times, drug amounts given and amounts discarded, and the order of services so the correct initial, sequential and concurrent codes are billed. We track authorizations by drug and date range so treatment is not delayed by an expired approval. Our team works inside your EHR and reviews claims against applicable billing, coding and payer-specific rules (10,000+ in our workflow) before submission to help identify preventable errors.
Common codes we work with in oncology
| Code | Description |
|---|---|
| 96413 | Chemotherapy administration, IV infusion, up to 1 hour, single or initial drug |
| 96415 | Chemotherapy IV infusion, each additional hour |
| 96417 | Chemotherapy IV infusion, each additional sequential infusion of a different drug, up to 1 hour |
| 96409 | Chemotherapy administration, IV push, single or initial drug |
| 96401 | Chemotherapy administration, subcutaneous or intramuscular, non-hormonal antineoplastic |
| 96375 | Therapeutic IV push, each additional sequential push of a new drug |
| J9271 | Injection, pembrolizumab, 1 mg |
| 36591 | Collection of blood specimen from a completely implantable venous access device |
CPT is a registered trademark of the American Medical Association. Payer rules vary; we check each payer's current policy.
Where oncology practices lose revenue
Administration code hierarchy
Only one initial service is billed per encounter, and chemotherapy outranks therapeutic infusions, which outrank hydration. A day with a 90-minute chemo infusion and a premedication push might be billed as 96413, 96415 and 96375. Getting the hierarchy wrong is a frequent reason for underpayment.
Drug units, waste and JW/JZ modifiers
J-codes are billed in the units the HCPCS descriptor defines, such as J9271 (pembrolizumab, 1 mg). For Medicare Part B, discarded drug from a single-dose vial is reported on a separate line with modifier JW, and modifier JZ is required when nothing was discarded. Missing JZ triggers edits.
Prior authorization by regimen
Commercial payers and Medicare Advantage plans usually authorize by drug, dose and number of cycles. A change in regimen, a new biosimilar or an extra cycle can fall outside the approved authorization. We match each claim to its authorization before submission.
Biosimilars and payer-preferred products
Many payers now require a specific biosimilar, billed with its own Q-code such as Q5107 or Q5118. Administering the reference product when a plan prefers a biosimilar can lead to a denied drug line even when the administration code pays.
What else affects oncology revenue
A/R challenges in oncology
Oncology A/R is driven by drug lines. One infusion claim can carry thousands of dollars in J-codes, so a single denial for units, NDC or authorization dates moves the whole aging report. Drug payments are often tied to ASP-based contract rates, and underpayments are easy to miss without line-level review, so we work high-dollar drug lines first and compare each payment to your contract.
Credentialing considerations
Medical oncologists, radiation oncologists and advanced practice providers each need enrollment with every payer, and each infusion site must be on the practice's Medicare enrollment before services are billed from it. Opening a new infusion location means updating PECOS and commercial plan rosters ahead of time. Value-based programs such as CMS's Enhancing Oncology Model have their own participation agreements and reporting rules.
Payer considerations
Many commercial and Medicare Advantage plans route oncology drug authorizations through benefit managers such as Evolent or Carelon, which review regimens against NCCN-based pathways. Some plans require certain drugs to come from a specialty pharmacy (white bagging) instead of buy-and-bill. Medicare requires the JW modifier for discarded amounts from single-dose containers and JZ when nothing is discarded.
Oncology coding details that affect payment
ICD-10 considerations
When a visit is solely for chemotherapy or immunotherapy, Z51.11 or Z51.12 is listed first, followed by the cancer being treated. Treatment directed at the primary site is coded to the primary malignancy, while treatment aimed at metastases lists the secondary site codes in C77 to C79. A Z85 personal history code is used only once the cancer has been removed and no further treatment is directed at it, so continuing to code active cancer after treatment ends, or history codes during treatment, both cause problems. Adverse effects of chemotherapy pair the condition with a T45.1X5 code, such as D70.1 (agranulocytosis secondary to cancer chemotherapy) or D64.81 for anemia due to antineoplastic chemotherapy, and breast cancer codes in C50 require laterality.
Modifiers to watch
| JZ | Placed on each single-dose drug line when no drug was discarded, which Medicare requires for Part B drugs. |
|---|---|
| 25 | Added to the E/M on an infusion day when the physician manages a separate problem beyond the usual pre-treatment assessment. |
| XU or 59 | Used when a second initial infusion code is reported because the protocol required two separate IV access sites. |
| Q0 | Applied to an investigational item or service billed under a qualifying clinical trial, with Z00.6 and the trial's identifier on the claim. |
| Q1 | Used on routine care billed during a qualifying clinical trial so Medicare processes it under its clinical trial policy. |
Global periods
Infusion and injection codes have no global period. Port placement (36561) carries a 10-day global and bone marrow biopsy (38221) a 0-day global, so a visit during a port's global needs an unrelated reason and modifier 24.
Medicare considerations
Medicare pays most Part B drugs at average sales price plus 6%, and qualifying biosimilars receive a temporarily higher add-on based on the reference product's ASP under the Inflation Reduction Act. The same law created quarterly coinsurance adjustments for certain Part B drugs whose prices rise faster than inflation, which can change what the patient owes. Medicare covers routine costs in qualifying clinical trials under NCD 310.1.
Oncology billing KPIs to track
- Drug line denial rate. One denied J-code line can outweigh a day of visits, so drug denials are tracked separately from administration denials.
- Drug payment compared with contract rate. ASP-based contract rates shift quarterly, and line-level comparison is the only reliable way to find underpayments.
- Authorization match by cycle. Claims for cycles beyond the approved count or date range deny even when the regimen was approved.
- Waste reporting accuracy. Missing or incorrect JW and JZ lines trigger edits and can draw payer audits of drug billing.
Oncology billing audit checklist
- Compare infusion start and stop times with the administration codes and hierarchy billed.
- Confirm drug units match the HCPCS descriptor and the dose documented, with NDC where required.
- Check that every single-dose drug line carries JZ or a separate JW line for waste.
- Verify the authorized drug, dose and cycle count match each claim's dates of service.
- Review payer biosimilar preferences against the product administered.
- Confirm clinical trial claims carry Q0 or Q1, Z00.6 and the trial identifier.
Related: Oncology coding · denial management · RCM · billing audit · Oncology billing in Texas · Epic billing · athenahealth billing · RCM resources
How SFA runs oncology billing
We review your current drug list, payer mix and authorization process to find where claims are being underpaid or delayed.
Our team tracks authorizations by patient, drug and cycle and flags anything expiring before the next treatment date.
Coders verify infusion times, drug units and waste documentation, with a 24-hour target for submitting clean claims after final review.
We work denials and underpaid drug lines, appealing with the documentation and NCCN or payer policy support needed.
The services that matter most for oncology
Eligibility Verification & Prior Authorization
Drug and regimen-level prior authorizations have to be in place and current before every cycle.
Learn moreMedical Coding
Infusion hierarchy, drug unit math and waste reporting decide whether a high-dollar claim pays in full.
Learn moreA/R Recovery
Unpaid drug lines are large, and older oncology A/R often holds a significant amount of recoverable revenue.
Learn moreWhat practices typically see with SFA
Averages and selected client results. Your free audit shows where your own numbers stand today.
Target for the claims we manage, not a measured average.
Highest improvement seen in selected client results.
Largest drop in A/R days seen in selected client results.
Targeted for submission within 24 hours after final review.
From primary care and nurse practitioners to surgery and imaging.
We work inside the system your practice already uses.
Results vary by practice, specialty, payer mix, claim volume, billing history, documentation and other factors. Performance figures represent average or selected client results and are not guarantees of future performance. The 95% figure is a clean-claim target, not a measured cohort. The client-results page does not include a measurement period, starting collections, or practice size.
Oncology billing questions
How do you bill hydration given with chemotherapy?
Hydration given at the same encounter as chemotherapy is reported with add-on code 96361 only when it is medically necessary and runs at least 31 minutes beyond what is incidental to the chemo. The initial service code goes to the chemotherapy infusion.
What is the JZ modifier?
Medicare requires JZ on Part B drugs from single-dose containers when no drug was discarded. When some amount was discarded, the waste is billed on its own line with JW.
Can you handle buy-and-bill drugs and specialty pharmacy drugs?
Yes. Buy-and-bill drugs are billed with the J-code and units on your claim. Drugs supplied by a specialty pharmacy are billed by the pharmacy, and your claim carries only the administration code, which we watch for so drugs are not billed twice.
Do you bill radiation oncology?
Yes. Radiation oncology has its own planning, simulation, delivery and management codes, and Medicare uses some HCPCS G-codes in place of CPT codes for freestanding centers. We confirm the correct code set for each payer.
How quickly can you start?
We can typically begin within 24 hours of receiving system access. Most practices start with a free practice audit, where we review your billing and walk you through where revenue may be slipping.
Related specialties
See what your oncology billing is missing
Send us a few details and an RCM specialist who knows oncology will review where claims are denied, underpaid or left unbilled.
- A clear walkthrough of what we find
- Reply typically within one business day
- No commitment
Request your free practice audit
An RCM specialist typically replies within one business day.